$14.21
2.14% today
Nasdaq, Apr 03, 06:47 pm CET
ISIN
US53635D2027
Symbol
LQDA
Sector
Industry

Liquidia Technologies, Inc. Stock price

$14.52
-0.35 2.35% 1M
+4.52 45.13% 6M
+2.76 23.47% YTD
-0.86 5.59% 1Y
+7.47 105.81% 3Y
+9.33 179.77% 5Y
+3.42 30.81% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.01 0.07%
ISIN
US53635D2027
Symbol
LQDA
Sector
Industry

Key metrics

Market capitalization $1.24b
Enterprise Value $1.07b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 76.36
P/S ratio (TTM) P/S ratio 88.47
P/B ratio (TTM) P/B ratio 15.91
Revenue growth (TTM) Revenue growth -19.97%
Revenue (TTM) Revenue $14.00m
EBIT (operating result TTM) EBIT $-121.29m
Free Cash Flow (TTM) Free Cash Flow $-98.37m
Cash position $176.48m
EPS (TTM) EPS $-1.66
P/E forward negative
P/S forward 28.41
EV/Sales forward 24.52
Short interest 21.69%
Show more

Is Liquidia Technologies, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Liquidia Technologies, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Liquidia Technologies, Inc. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Liquidia Technologies, Inc. forecast:

Buy
90%
Hold
10%

Financial data from Liquidia Technologies, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
14 14
20% 20%
100%
- Direct Costs 7.08 7.08
70% 70%
51%
6.92 6.92
48% 48%
49%
- Selling and Administrative Expenses 79 79
89% 89%
567%
- Research and Development Expense 47 47
11% 11%
333%
-119 -119
68% 68%
-851%
- Depreciation and Amortization 2.20 2.20
14% 14%
16%
EBIT (Operating Income) EBIT -121 -121
65% 65%
-866%
Net Profit -130 -130
66% 66%
-931%

In millions USD.

Don't miss a Thing! We will send you all news about Liquidia Technologies, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Liquidia Technologies, Inc. Stock News

Neutral
GlobeNewsWire
2 days ago
Liquidia Corporation will provide an overview of the company's business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference.
Neutral
GlobeNewsWire
2 days ago
Liquidia Corporation will provide an overview of the company's business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference.
Neutral
GlobeNewsWire
6 days ago
The U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder.
More Liquidia Technologies, Inc. News

Company Profile

Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC.

Head office United States
CEO Roger Jeffs
Employees 157
Founded 2004
Website www.liquidia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today